Holen Sie sich die Stockscreener-App
7.89
3.68%
0.28
Schlusskurs vom Vortag:
$7.61
Offen:
$7.72
24-Stunden-Volumen:
426.27K
Relative Volume:
1.07
Marktkapitalisierung:
$528.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.44M
KGV:
-3.5004
EPS:
-2.254
Netto-Cashflow:
$-103.79M
1W Leistung:
+13.36%
1M Leistung:
+17.94%
6M Leistung:
+24.45%
1J Leistung:
+114.40%
1-Tages-Spanne:
$7.485
$8.03
1-Wochen-Bereich:
$6.86
$8.03
52-Wochen-Spanne:
$2.65
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Firmenname
Engene Therapeutics Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
7.89 | 528.55M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | WBB Securities | Buy |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten
Invus-group and Avicenna report 6.7% and 1.1% stakes in enGene (ENGN) - Stock Titan
Piper Sandler reiterates Engene stock rating on clinical data outlook - Investing.com
Piper Sandler Maintains EnGene Therapeutics(ENGN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Increase in Short Interest - MarketBeat
H.C. Wainwright Keeps Their Buy Rating on enGene Holdings (ENGN) - The Globe and Mail
H.C. Wainwright Maintains EnGene Therapeutics(ENGN.US) With Buy Rating, Maintains Target Price $25 - Moomoo
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. - The National Law Review
ENGN | enGene Therapeutics Inc. Common Insider Trading - Quiver Quantitative
WBB Securities initiates coverage of Engene Therapeutics (ENGN) with buy recommendation - MSN
Is enGene (ENGNW) stock facing uncertainty (-5.10%) 2026-04-20Trending Social Stocks - Newser
Wall Street Zen Downgrades enGene (NASDAQ:ENGN) to Sell - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Growth in Short Interest - MarketBeat
ENGN Options Volatility — NASDAQ:ENGN - TradingView
WBB Securities Initiates a Buy Rating on enGene Holdings (ENGN) - The Globe and Mail
WBB Securities Initiates EnGene Therapeutics(ENGN.US) With Buy Rating, Announces Target Price $21.5 - Moomoo
ENGN Options Chain — NASDAQ:ENGN - TradingView
Engene Therapeutics Inc. Live Share Prices and Trades. ENGNW.US Live Streaming Share Prices. - London South East
ENGN Initiates Coverage On enGene Therapeutics -- Rating Set to Buy - GuruFocus
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trap2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
WBB Securities Initiates Coverage on enGene (NASDAQ:ENGN) - MarketBeat
enGene Therapeutics (NASDAQ:ENGN) Stock, Unusual Options - Benzinga
Published on: 2026-04-13 18:10:23 - baoquankhu1.vn
Aug Opening: Will enGene Holdings Inc stock hit new highs in YEAR2026 Support & Resistance & Risk Managed Investment Signals - baoquankhu1.vn
Revenue Check: Is enGene Holdings Inc forming bullish engulfing patterns2026 Risk Factors & High Return Trade Guides - baoquankhu1.vn
EBIT per share of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
EBITDA margin % of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics (FRA:S0N0) Cyclically Adjusted PS Ratio : (As of Apr. 16, 2026) - GuruFocus
Cash per share of enGene Therapeutics Inc. – FWB:S0N0 - TradingView
Total liabilities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView
Total liabilities & shareholders' equities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA29286X1015 - marketscreener.com
S0N0: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc. Changes Name and Prepares for 2027 Commercial Launch of Detalimogene Voraplasmid for High-Risk NMIBC - Minichart
enGene Therapeutics Inc.: Fundamental Analysis and Financial Ratings | ENGN | CA29286X1015 - marketscreener.com
ENGN: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Rebrands as Company Nears Commercialization - TipRanks
Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan
Bull Run: What analysts say about enGene Holdings Inc Equity Warrant stockFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Chipmakers Recap: How does enGene Holdings Inc compare to its peers2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
ENGE HLDGNPV: Shareholders Board Members Managers and Company Profile | CA29286M1059 - marketscreener.com
Is enGene Holdings Inc benefiting from interest rate changes2026 Market Overview & Daily Entry Point Alerts - baoquankhu1.vn
ENGNW Stock Warrant Price and Chart — NASDAQ:ENGNW - TradingView — Track All Markets
Smart Money: Is enGene Holdings Inc Equity Warrant stock a value trapMarket Risk Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
EnGene Holdings Inc. will Change its Name to enGene Therapeutics Inc - marketscreener.com
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval - National Today
enGene Announces Name Change to enGene Therapeutics Inc. - PharmiWeb.com
enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks
enGene Holdings changes name to enGene Therapeutics - Investing.com
enGene announces name change to enGene Therapeutics - TipRanks
Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):